US Patent 11,117,871: Enarodustat Crystalline Forms, Claim Scope, Patent Strength, and Generic Entry Risk
US Patent 11,117,871 protects two crystalline forms, CS1 and CS9, of enarodustat, also known as JTZ-951, an oral hypoxia-inducible factor prolyl hydroxylase inhibitor. The patent also covers specified crystallization processes, pharmaceutical compositions containing either form, and methods of treating anemia with the forms. It does not broadly claim enarodustat, every polymorph, salts, amorphous material, or all HIF-PH inhibitor uses.
The patent issued on September 14, 2021. Its commercial significance depends on whether the claimed forms are used in an approved product, whether the patent is listed in the FDA Orange Book, and whether competing manufacturers can avoid the claimed XRPD signatures and manufacturing routes. The supplied claims indicate a technically narrow but potentially meaningful solid-state patent.
What drug and active ingredient does US Patent 11,117,871 protect?
The claimed compound is enarodustat, identified chemically as N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine. Enarodustat is an HIF prolyl hydroxylase inhibitor developed for anemia associated with chronic kidney disease.
The patent does not claim the active ingredient in all physical forms. Its central protection is directed to two named crystalline forms:
| Feature |
CS1 |
CS9 |
| Independent product claim |
Claim 1 |
Claim 6 |
| Required XRPD peaks |
6.4°, 7.5°, 7.9° |
4.6°, 6.6°, 21.1° |
| Additional peaks |
17.2°, 21.0°, 24.0°, 19.3° |
9.4°, 20.2°, 24.2° |
| Pharmaceutical composition |
Claim 11 |
Claim 13 |
| Anemia treatment method |
Claim 12 |
Claim 14 |
| Human-treatment limitation |
Claim 15 |
Claim 16 |
| Process claims |
Claims 3-5 |
Claims 8-10 |
All XRPD values use CuKα radiation and include a ±0.2° tolerance, except that claim 2 contains the apparent text “24.0°±0.2%.” In context, that notation is likely a drafting error for degrees, but the issued claim language controls unless corrected through an appropriate legal mechanism. (U.S. Patent No. 11,117,871, 2021).
What are the independent claims in US Patent 11,117,871?
The patent has six principal claim categories.
CS1 crystalline-form claim
Claim 1 requires crystalline form CS1 and three characteristic XRPD peaks at approximately 6.4°, 7.5°, and 7.9°. A material lacking one of those required peaks may have a substantial non-infringement argument, subject to claim construction and analytical reproducibility.
Claim 2 narrows CS1 by requiring one or more additional peaks. The claim does not require every listed secondary peak, only one or more.
CS1 manufacturing claims
Claim 3 covers two routes:
- Dissolution in tetrahydrofuran, acetone, methyl isobutyl ketone, or specified mixtures, followed by evaporation at 10°C to 50°C.
- Dissolution in 1,4-dioxane, addition of water, crystallization, separation, and drying.
Claims 4 and 5 narrow the operating conditions. Claim 5 specifically identifies acetone or methyl isobutyl ketone and a two-hour crystallization period for the dioxane-water route.
CS9 crystalline-form claim
Claim 6 requires CS9 and XRPD peaks at approximately 4.6°, 6.6°, and 21.1°. Claim 7 adds optional secondary peaks at 9.4°, 20.2°, and 24.2°.
CS9 manufacturing claims
Claim 8 covers two processes:
- Methyl tert-butyl ether with a polymer mixture containing equal masses of polycaprolactone, polyoxyethylene, polymethyl methacrylate, hydroxyethyl cellulose, and sodium alginate, followed by evaporation at 10°C to 70°C.
- Ethyl acetate and ethanol in a volume ratio from 1:10 to 10:1, followed by evaporation at 10°C to 70°C.
Claims 9 and 10 narrow the process to 50°C and, for the ethyl acetate-ethanol route, a 1:1 volume ratio.
How strong are the CS1 and CS9 product claims?
The product claims have moderate technical enforceability but limited breadth. They are defined by XRPD patterns rather than by a broad structural formula alone.
Strengths
The claims use multiple required peaks. That is stronger than a claim relying on one diagnostic peak because an accused product must be assessed against a pattern rather than a single diffraction signal.
The ±0.2° ranges provide some tolerance for instrument conditions, sample preparation, and measurement variation. They also create a defined analytical boundary for infringement testing.
The composition and treatment claims extend protection beyond bulk crystalline material. A pharmaceutical product containing CS1 or CS9 could fall within claims 11 or 13 even if the form is combined with conventional excipients.
Limitations
The claims do not expressly cover:
- Amorphous enarodustat
- Other enarodustat polymorphs
- Enarodustat salts or solvates not meeting the claimed XRPD pattern
- Co-crystals outside CS1 and CS9
- Formulations containing only a different physical form
- Manufacturing routes that produce CS1 or CS9 through different conditions, unless the resulting material is covered by the product or composition claims
A generic manufacturer could attempt to develop a non-infringing polymorph, amorphous form, salt, or formulation. That strategy would require rigorous solid-state characterization because processing, milling, humidity, temperature, and excipients can cause phase conversion.
What formulations are protected by US Patent 11,117,871?
Claims 11 and 13 protect pharmaceutical compositions containing a therapeutically effective amount of CS1 or CS9 and pharmaceutically acceptable carriers, diluents, or excipients.
These claims are broad as to excipient selection. They do not specify tablets, capsules, suspensions, coatings, release profiles, particle size, or dosage strength. The patent therefore reaches conventional oral dosage forms if the active ingredient is present as the claimed crystalline form.
The claims do not independently protect a particular formulation technology. There is no express limitation to controlled release, enteric coating, nanoparticles, injectable delivery, or a named excipient system.
What methods of use are protected?
Claims 12 and 14 cover treatment of anemia with CS1 or CS9. Claims 15 and 16 narrow the respective methods to human subjects.
The treatment claims are narrower than a general claim to use of enarodustat because they require the specific crystalline form. They also do not expressly identify a particular anemia subtype, renal disease stage, dose, dosing frequency, hemoglobin target, or concomitant therapy.
Potentially relevant anemia indications include chronic kidney disease anemia, but the issued claims as provided use the broader term “anemia.” Claim scope remains subject to the specification, prosecution history, written-description support, enablement, and ordinary claim-construction principles.
When does US Patent 11,117,871 lose exclusivity?
The patent issued on September 14, 2021. U.S. utility patents generally expire 20 years from the earliest effective nonprovisional filing date, subject to patent-term adjustment, patent-term extension, terminal disclaimers, and applicable priority rules. The issue date alone does not establish the expiration date. (35 U.S.C. §§ 154, 156).
The claims supplied do not identify the priority chain, patent-term adjustment, or any terminal disclaimer. Accordingly, the precise expiration date cannot be calculated from the claims alone. Any commercial freedom-to-operate analysis must confirm the continuity data and term calculation in the USPTO record.
Patent-term extension under 35 U.S.C. § 156 would require an eligible FDA regulatory approval and satisfaction of statutory requirements. No such extension is established by the patent claims.
What is the Orange Book status of enarodustat and this patent?
Enarodustat does not have an established FDA-approved U.S. reference product identified in the supplied record. As a result, there is no demonstrated Orange Book listing for US Patent 11,117,871.
Orange Book listing is relevant only if an NDA holder lists the patent for an approved drug and the patent claims the drug, an approved method of use, or a qualifying product characteristic. A crystalline-form patent may be listable in certain circumstances, but listing is not automatic and depends on the approved product and FDA listing requirements. (FDA, 2024a).
Without an FDA-approved U.S. enarodustat product, the patent does not presently create a conventional Orange Book patent-certification pathway comparable to an approved small-molecule product with listed patents.
Are there Paragraph IV challenges to US Patent 11,117,871?
No Paragraph IV challenge is established by the supplied information.
Paragraph IV certifications arise in an Abbreviated New Drug Application referencing an approved listed drug. If enarodustat lacks an FDA-approved reference product and the patent is not listed in the Orange Book, a conventional ANDA Paragraph IV dispute would not ordinarily be the principal U.S. entry route.
A future applicant could face different issues depending on regulatory strategy, including:
- A 505(b)(2) application
- An NDA-based development program
- An ANDA if an FDA reference product becomes available
- Patent litigation based on direct infringement, induced infringement, or contributory infringement
The absence of a known Paragraph IV case does not eliminate development risk. It means that the principal risk is currently patent validity and freedom-to-operate risk rather than a confirmed ANDA challenge.
What patent litigation affects US Patent 11,117,871?
No litigation, settlement, or license affecting US Patent 11,117,871 is established by the claim text. The patent should be checked in the USPTO Patent Center and PACER for post-issuance litigation, claim-construction rulings, inter partes review petitions, post-grant proceedings, or declaratory-judgment actions.
The most likely dispute issues would be:
- Whether the accused material actually matches CS1 or CS9 under validated XRPD testing.
- Whether the ±0.2° ranges are sufficiently definite.
- Whether the forms were adequately described and enabled.
- Whether the patent claims priority over earlier polymorph disclosures.
- Whether a generic process practices each required solvent, polymer, temperature, and evaporation limitation.
- Whether a composition contains a claimed form at commercially meaningful levels.
No settlement agreement can be inferred from the patent itself.
Which companies are challenging enarodustat patent rights?
No publicly established U.S. challenger is identified in the supplied information. Enarodustat has competed or may compete clinically with other HIF-PH inhibitors, including daprodustat, roxadustat, vadadustat, and molidustat. Those products have separate active ingredients and separate patent estates.
Competition from other HIF-PH inhibitors does not directly invalidate US Patent 11,117,871. It can reduce the commercial value of enarodustat exclusivity by limiting market share, pricing power, and development incentives.
How does this patent compare with a broad API patent?
| Protection type |
Present in US 11,117,871? |
Commercial effect |
| Enarodustat chemical structure |
No broad claim shown |
Limited protection against alternative forms |
| CS1 polymorph |
Yes |
Direct solid-state barrier |
| CS9 polymorph |
Yes |
Separate solid-state barrier |
| CS1 manufacturing process |
Yes |
Process-specific protection |
| CS9 manufacturing process |
Yes |
Process-specific protection |
| Pharmaceutical composition |
Yes |
Product-level protection if form is present |
| Anemia treatment |
Yes |
Method-of-use protection |
| Specific dose or regimen |
No |
Limited prescribing-regimen coverage |
| Specific tablet formulation |
No |
No express dosage-form technology |
The patent is best characterized as a polymorph and manufacturing patent with associated composition and method-of-use claims. It is not a complete substitute for a broad compound patent, formulation patent, or approved-use patent.
What generic entry risks exist?
A generic or follow-on developer faces four principal risks.
First, analytical risk exists if the proposed product converts into CS1 or CS9 during manufacturing, storage, granulation, compression, or dissolution testing.
Second, process risk exists if the manufacturer uses the claimed solvent systems, evaporation temperatures, polymer mixture, or ethyl acetate-ethanol ratio.
Third, composition-claim risk exists if the final dosage form contains either claimed crystalline form, even when the manufacturer did not intentionally target that form.
Fourth, regulatory risk exists if the applicant must demonstrate pharmaceutical equivalence or rely on a U.S. reference product whose active ingredient is supplied as CS1 or CS9.
The most defensible design-around would generally use a fully characterized non-infringing solid form and a process outside the claimed solvent and evaporation limitations. That design-around would still require stability, bioequivalence, manufacturability, and regulatory support.
Key Takeaways
- US Patent 11,117,871 covers enarodustat crystalline forms CS1 and CS9.
- CS1 is defined primarily by XRPD peaks at 6.4°, 7.5°, and 7.9°.
- CS9 is defined primarily by XRPD peaks at 4.6°, 6.6°, and 21.1°.
- The patent includes composition claims and anemia-treatment claims for both forms.
- The process claims are narrow and identify specific solvents, polymers, temperatures, and crystallization conditions.
- The patent does not broadly claim all enarodustat, all polymorphs, salts, or amorphous forms.
- No confirmed U.S. Orange Book listing, Paragraph IV challenge, litigation, or settlement is established from the supplied information.
- Exact patent expiration requires review of the complete priority chain and any patent-term adjustments or disclaimers.
- Generic entry is most exposed where the proposed product contains CS1 or CS9, even if the competing manufacturer uses a different process.
FAQs
Is enarodustat the same compound named in US Patent 11,117,871?
Yes. The chemical name in the claims corresponds to enarodustat, also known as JTZ-951.
Can a product infringe if its XRPD pattern has only two of the three required CS1 peaks?
That depends on the complete diffraction pattern, measurement conditions, claim construction, and evidence of equivalence. The literal CS1 claim requires all three listed characteristic peaks.
Does the patent cover enarodustat tablets made with different excipients?
Claims 11 and 13 can cover pharmaceutical compositions containing CS1 or CS9 with pharmaceutically acceptable carriers, diluents, or excipients. The claims do not require a particular excipient.
Does a different manufacturing process avoid the patent?
A different process may avoid a process claim, but it may not avoid the product, composition, or treatment claims if it still produces or uses CS1 or CS9.
Are biosimilar rules relevant to enarodustat?
No. Enarodustat is a chemically synthesized small molecule, not a biologic. Generic-drug and small-molecule patent rules are more relevant than the biosimilar pathway under the Public Health Service Act.
References
Food and Drug Administration. (2024a). Approved drug products with therapeutic equivalence evaluations. U.S. Department of Health and Human Services.
Food and Drug Administration. (2024b). Purple Book: Database of licensed biological products. U.S. Department of Health and Human Services.
United States Code. (2023). 35 U.S.C. §§ 154, 156.
U.S. Patent No. 11,117,871. (2021). Crystalline forms of N-[(1,3-dicyclohexylhexahydro-2,4,6-trioxo-5-pyrimidinyl)carbonyl]glycine. United States Patent and Trademark Office.